ImmunoPrecise Antibodies Ltd. Files 6-K
Ticker: HYFT · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K, likely with news. Check Exhibit 99.1 for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 4, 2024, reporting a press release dated June 3, 2024. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates ImmunoPrecise Antibodies Ltd. is providing an update or making an announcement to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain immediate financial or operational risks.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Chief Financial Officer
- June 3, 2024 (date) — Press Release Date
- June 4, 2024 (date) — Filing Date
FAQ
What is the subject of the press release filed as Exhibit 99.1?
The provided text does not specify the subject of the press release dated June 3, 2024, only that it is included as Exhibit 99.1.
What is the principal executive office address of ImmunoPrecise Antibodies Ltd.?
The principal executive offices are located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Who signed the Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
The Form 6-K was signed by Kristin Taylor, Chief Financial Officer.
What is the SEC file number for ImmunoPrecise Antibodies Ltd.?
The SEC file number is 001-39530.
Does ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or Form 40-F?
The company indicates it files annual reports under Form 20-F.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-04 16:11:55
Filing Documents
- form6k.htm (6-K) — 4KB
- exhibit99-1.htm (EX-99.1) — 10KB
- exhibit99-1x001.jpg (GRAPHIC) — 4KB
- 0001062993-24-011788.txt ( ) — 21KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: June 4, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Press Release dated June 3, 2024